Sanofi (SNYNF) Stock Price, News & Analysis

Company Overview

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Key Stats

• Today's Range: $93.14 to $93.14
• 50-Day Range: $91.81 to $102.00
• 52-Week Range: $90.05 to $122.03
• Volume: 21,550 shs
• Average Volume: 39,825 shs
• Market Capitalization: N/A
• P/E Ratio: 30.20
• Dividend Yield: 3.01%
• Price Target: N/A
• Consensus Rating: N/A

Sanofi Stock Analysis - MarketRank™

Sanofi scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Sanofi.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sanofi is 30.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 279.52.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sanofi is 30.20, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.78.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Sanofi has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sanofi has recently decreased by 29.63%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

Sanofi is a leading dividend payer. It pays a dividend yield of 4.13%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Sanofi does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Sanofi is 90.78%. Payout ratios above 75% are not desirable because they may not be sustainable.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -2.26

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Sanofi has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sanofi has recently decreased by 29.63%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.22

News Sentiment

Sanofi has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Sanofi this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sanofi insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 30.06% of the stock of Sanofi is held by institutions.

SNYNF Stock Analysis - Frequently Asked Questions

How have SNYNF shares performed this year?

Sanofi's stock was trading at $95.1001 at the start of the year. Since then, SNYNF shares have decreased by 2.1% and is now trading at $93.1440.

How do I buy shares of Sanofi?

Shares of SNYNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/10/2025
• Next Earnings (Estimated): 10/24/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:SNYNF
• CIK: 1121404
• Web: www.sanofi.com
• Phone: (315) 377-4000
• Fax: N/A
• Employees: 91,600
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 30.20
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A